



30 August 2022

ASX ANNOUNCEMENT

Board Changes: Jan West AM appointed as Non-executive Director; Judith Downes to retire

The Board of ImpediMed Limited (ASX:IPD) (**ImpediMed, Company**) is pleased to announce the appointment of Mrs Jan West AM as an independent Non-executive Director, effective today.

Jan is an accomplished Non-executive Director with over 20 years as a partner at Deloitte. Her experience covers public sector, community and private organisations. She has recently been a Director of Australia Post, Australian Red Cross Society, Neurosciences Victoria and Dairy Australia. Additionally, Jan was the Past President of the Chartered Accountants Australia and New Zealand and an Independent Member, Audit and Risk Management Committee of the Department of Health and Human Services Victoria.

"I am excited to begin my relationship with ImpediMed as a Director," commented Mrs West. "The Company's new interim leadership and reinvigorated plans for growth and reimbursement make for an exciting future."

Commenting on the appointment, ImpediMed's Chair Don Williams said, "We are delighted to welcome Jan at an exciting time for the Company. She brings over 30 years of experience as a Non-Executive Director combined with over 20 years experience as a Deloitte partner. Her deep financial, governance and risk management expertise will be of great value to the Company through its next phase of growth."

Also today, the Company announces that Ms Judith Downes, Chair of ImpediMed's Audit and Risk Management Committee, will not stand for re-election as a Non-Executive Director at the 2022 Annual General Meeting.

On behalf of the Board, ImpediMed's Chair Don Williams extended his gratitude to Ms Downes for her exceptional contribution to the Company during a period of significant growth.

Judith has served on the Board for the past five years and has ably Chaired the Audit and Risk Management Committee, served on the Nomination Committee and Chaired the Due Diligence Committee for Capital Raisings.

Mr Williams said "Judith is a highly regarded and dedicated member of the Board. ImpediMed has greatly benefitted from her financial knowledge, wise council and pragmatic approach to ImpediMed's financial position over the past five years. My colleagues and I are extremely grateful for Judith's invaluable service."

Judith Downes commented "Now is the perfect time to renew the Board with fresh perspectives as the Company accelerates its commercialisation efforts and moves into the next phase of its journey. I am very confident for the future of ImpediMed under the stewardship of the Board and an experienced management team led by David Anderson, Interim CEO. I wish the Company every success."

Mrs West will assume the role of Chair of the Audit and Risk Management Committee on the departure of Ms Downes.

Approved for release by the Chair of ImpediMed Limited, Mr Donald Williams.

Contact Details

Donald Williams

T: +1-760-585-2146

E: dwilliams@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.